Related Experiment Video
Updated: Oct 19, 2025
08:58
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
16.2K
Abnormal m6A modification in non-alcoholic fatty liver disease
Zhenzhou Li1, Jing Qi2, Huaizheng Liu2
1Department of Emergency, Third Xiangya Hospital, Central South University, Changsha 410013, China. lizhenzhou@csu.edu.cn.
Summary
RNA N6-methyladenosine (m6A) modification levels are altered in non-alcoholic fatty liver disease (NAFLD) liver tissues. This study reveals changes in m6A methylation, offering insights into NAFLD's development.
Area of Science:
- Biochemistry
- Molecular Biology
- Genomics
Background:
- Non-alcoholic fatty liver disease (NAFLD) is a growing health concern.
- N6-methyladenosine (m6A) methylation is implicated in lipid metabolism.
- The role of m6A modification in NAFLD pathogenesis is not well understood.
Purpose of the Study:
- To investigate alterations in RNA m6A methylation in NAFLD liver tissues.
- To provide a basis for understanding m6A's role in NAFLD.
- To explore potential therapeutic targets related to m6A.
Main Methods:
- Liquid chromatography-mass spectrometry (LC-MS) for m6A quantification.
- Methylated RNA immunoprecipitation (MeRIP) coupled with microarray analysis of mRNAs and lncRNAs.
- Gene Ontology (GO) and KEGG pathway analysis for functional annotation.
- Validation of microarray findings using MeRIP and RT-qPCR.
Main Results:
- Significant differences in m6A modification were observed in 176 mRNAs and 44 lncRNAs in NAFLD tissues.
- The majority of differentially modified mRNAs (161) and lncRNAs (37) were hypomethylated.
- Enrichment analysis indicated involvement in carboxylic acid metabolism and transcriptional regulation.
Conclusions:
- Altered m6A modification profiles are characteristic of NAFLD liver tissues.
- These changes in m6A methylation may play a functional role in NAFLD progression.
- Further research into m6A's impact on NAFLD pathophysiology is warranted.
